LFG
TGTX icon

Larson Financial Group’s TG Therapeutics TGTX Stock Holding History

Larson Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$300 – 3790
2025
Q4 		$300 Hold
300
– – ﹤0.01% 3213
2025
Q3 		$1.94K Buy
+300
New +$9.88K ﹤0.01% 2721

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Larson Financial Group's TGTX Position: Q1 2026 in Review

Larson Financial Group increased its TG Therapeutics (TGTX) stake by 4.6% in Q1 2026, buying an estimated $9.71K and bringing the position to 7,490 shares worth $249K. The position accounts for 0.01% of the portfolio, ranked #653.

Larson Financial Group first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $254K in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Larson Financial Group held 7,490 shares of TG Therapeutics worth $249K as of Q1 2026.
  • Larson Financial Group bought 326 TG Therapeutics shares in Q1 2026, an estimated $9.71K.
  • TG Therapeutics made up 0.01% of Larson Financial Group's portfolio in Q1 2026, its #653 holding.
  • Larson Financial Group first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Larson Financial Group's TG Therapeutics position peaked at $254K in Q3 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.